Picture offshore wind farm

Open Access: World leading research into plasma physics...

Strathprints makes available scholarly Open Access content by researchers in the Department of Physics, including those researching plasma physics.

Plasma physics explores the '4th' state of matter known as 'plasma'. Profound new insights are being made by Strathclyde researchers in their attempts to better understand plasma, its behaviour and applications. Areas of focus include plasma wave propagation, non-linear wave interactions in the ionosphere, magnetospheric cyclotron instabilities, the parametric instabilities in plasmas, and much more.

Based on the REF 2014 GPA Scores, Times Higher Education ranked Strathclyde as number one in the UK for physics research.

Explore Open Access plasma physics research and of the Department of Physics more generally. Or explore all of Strathclyde's Open Access research...

The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection

Alsaadi, Manal and Italia, Jagdishbhai Laxmanbhai and Mullen, Alexander and Kumar, M.N.V Ravi and Candlish, A.A. and Williams, Roderick and Shaw, C.D. and Al-Gawhari, Fatima and Coombs, Graham and Wiese, Martin and Thomson, Alison and Puig-Sellart, M. and Wallace, J. and Sharp, A and Wheeler, Lee and Warn, Peter and Carter, Katharine (2012) The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. Journal of Controlled Release, 160 (3). pp. 685-691. ISSN 0168-3659

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

Amphotericin B (AMB) is used to treat both fungal and leishmanial infections, which are of major significance to human health. Clinical use of free AMB is limited by its nephrotoxicity, whereas liposomal AMB is costly and requires parenteral administration, thus development of novel formulations with enhanced efficacy, minimal toxicity and that can be applied via non-invasive routes is required. In this study we analysed the potential of non-ionic surfactant vesicles (NIV) given by nebulisation to deliver AMB to the lungs, liver and skin. Treatment with AMB-NIV resulted in significantly higher drug levels in the lungs and skin (p < 0.05) compared to similar treatment with AMB solution but significantly lower plasma levels (p < 0.05). Treatment with AMB-NIV resulted in a significant reduction in fungal lung burdens in a rat model of invasive pulmonary aspergillosis (p < 0.05) compared to treatment with the carrier alone. Treatment with AMB-NIV but not AMB solution significantly suppressed Leishmania donovani liver parasite burdens (p < 0.05) but could not inhibit the growth of cutaneous Leishmania major lesions. The results of this study indicate that aerosolised NIV enhanced pulmonary and hepatic delivery whilst minimising systemic exposure and toxicity.